Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis

Autor: D. Dodick, K. Bruining, Catherine M. Dalton, W. Morrison, D. Derrington, A. Bowling, J. Adams, J. Hebert, S. Curtis, Minhua Yang, Gareth J. Barker, R. E. Kramer, J. P. Kelly, D. G. MacManus, Shôn Lewis, L. Costley, K. Bracht, E. Drexler, M. Malikowski, R. S. Murray, Clive Hawkins, K. Markopoulou, David P. Richman, William A. Sheremata, K. Nelson, M. Yeung, R. Wolintz, I. Rozentsvit, Joel Oger, Luanne M. Metz, Kathleen Healey, Jonathan L. Carter, Zahid Latif, J. Trotter, C. Mathews, C. Wallace, Jinan Al-Omaishi, Katherine Riester, Todd L. Richards, C. Webb, B. Harwick, Thomas E. Conturo, C. Gibson, E. Prenger, G. Foster, J. Forsyth, Michael Kaufman, L D Blumhardt, D. A H Cross, J. Curlis, James D. Bowen, C. Coombs, V. Orpe, Mark A. Agius, Omar Khan, C. Martinez, J. Takata, C. Graves, S. Putman, J. Scott, A. Diedrich, L. Capolino, J. Leitch, Per Soelberg Sørensen, M. Cochran, M. Buonocore, P. English, Christopher F. O'Brien, M. J. Keilson, A. Schneider, A. Miller, George Rice, Alexandros Tselis, C. Middleditch, S. Dombrowski, L. Wang, H. Oltazewska, J. Lauber, J. Heuser, H. Lew, Virginia Devonshire, M. Zvartau-Hinds, M. Burke, D. Patry, Paul O'Connor, M. Chang, Katherine A. Miszkiel, Lauren Seeberger, David W. Bates, L. Sciarra, E. Riddle, Robert P. Lisak, Michael Panzara, David Miller, R. Follmer, T. Jaspen, M. Din, T. Pepple, Christina Caon

Publikováno v: Multiple Sclerosis Journal. 11:568-572

Background: Natalizumab, a humanized monoclonal IgG4 antibody, is an a4-integrin antagonist, which inhibits the migration of inflammatory cells into the central nervous system, a key pathogenic mechanism in multiple sclerosis (MS). In a six month, ph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38665639a011a220df8600c7e84283b2
https://doi.org/10.1191/1352458505ms1205oa